Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
Corporate Secretary 60 08/08/2019
Director TitleAgeSince
Director/Board Member 49 21/04/2020
Director/Board Member 60 07/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-2.23%-1.65%+61.34%+111.83% 5.62TCr
+4.60%+5.85%+54.47%+43.04% 4.38TCr
-2.10%+0.90%-13.46%-17.82% 2.33TCr
-2.92%-0.99%-3.72%+373.85% 2.13TCr
+3.22%+3.77%+19.92%-35.05% 1.58TCr
-0.67%+0.65%+14.86%-38.42% 1.56TCr
-1.41%-4.07%+25.97%+170.96% 1.32TCr
+3.07%+3.59%+25.54% - 1.2TCr
+4.95%+7.51%+123.21%+249.05% 1.19TCr
Average +0.66%+3.76%+34.24%+107.18% 2.37TCr
Weighted average by Cap. +0.39%+3.54%+38.00%+98.45%
Logo Nightstar Therapeutics PLC
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company's lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company's third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!